Tezepelumab in severe asthma: a profile of its use

<p>  </p> <p><strong>Declarations</strong></p> <p><strong>Funding</strong> The preparation of this review was not supported by any external funding.</p> <p><strong>Authorship and Conflict of interest</strong> Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p><strong>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</strong> not applicable</p> <p>Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a></p> <p><strong>Abstract</strong></p> <p>Tezepelumab (tezepelumab-ekko; TEZSPIRE®), a first-in-class monoclonal antibody targeting thymic stromal lymphopoietin, represents a novel, effective and generally well tolerated treatment option for patients with severe asthma across a wide range of phenotypes. In randomized, double-blind, phase 2 (PATHWAY) and phase 3 (NAVIGATOR) trials, subcutaneous tezepelumab demonstrated a significant reduction in annualized asthma exacerbation rate among patients with severe uncontrolled asthma. The efficacy was seen across a broad range of patients with different asthma endotypes and phenotypes, including eosinophilic and noneosinophilic asthma, allergic asthma, and type-2 low asthma. The efficacy was sustained over up to 104 weeks. Tezepelumab is generally well tolerated, with the most common adverse reactions being pharyngitis, arthralgia and back pain.</p> <p>© Springer Nature Switzerland AG 2023</p>